Combination of HDAC inhibitor MS-275 and IL-2 increased anti-tumor effect in a melanoma model via activated cytotoxic T cells

Journal of Dermatological Science

Volumn 75, Issue 2, 2014, Pages 140-147

  Kato, Yukihiko ^a,b   Yoshino, Ikuyo ^a   Egusa, Chizu ^a   Maeda, Tatsuo ^a   Pili, Roberto ^c   Tsuboi, Ryoji ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN TAMA MEDICAL CENTER   (Japan)

^c Roswell Cancer Park Institute   (United States)

Author keywords

Activated CD8 positive T lymphocyte; Combination therapy; Histone deacetylase inhibitor; Interleukin 2; Melanoma

Indexed keywords

ENTINOSTAT; INTERLEUKIN 2; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; PYRIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CD8+ CD69+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; FLOW CYTOMETRY; G1 PHASE CELL CYCLE CHECKPOINT; IN VITRO STUDY; IN VIVO STUDY; LYMPH NODE; LYMPHOCYTE ACTIVATION; MELANOMA; MELANOMA CELL LINE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; SURVIVAL RATE; T LYMPHOCYTE; TUMOR VOLUME; ANIMAL; C57BL MOUSE; CELL CULTURE; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYMOLOGY; GENETIC EPIGENESIS; GENETICS; IMMUNOLOGY; MELANOMA, EXPERIMENTAL; ORAL DRUG ADMINISTRATION; PATHOLOGY; SKIN NEOPLASMS; SPLEEN; SUBCUTANEOUS DRUG ADMINISTRATION; TIME;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZAMIDES; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIGENESIS, GENETIC; FEMALE; G1 PHASE CELL CYCLE CHECKPOINTS; HISTONE DEACETYLASE INHIBITORS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-2; LYMPH NODES; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; PYRIDINES; SKIN NEOPLASMS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS;

EID: 84903600086     PISSN: 09231811     EISSN: 1873569X     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2014.04.014     Document Type: Article

References (27)

1. Piccaluga P.P., Agostinelli C., Califano A., Rossi M., Basso K., Zupo S., et al. Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets. J Clin Invest 2007, 117:823-834.
2. Gilbert K.M., Boger S.R., Price P., Fifer E.K. T cell tolerance induced by histone deacetylase inhibitor is mediated by P21cip1. Immunopharmacol Immunotoxicol 2005, 27:545-564.
3. Woods D.M., Woan K., Cheng F., Wang H., Perez-Villarroel P., Lee C., et al. The antimelanoma activity of the histone deacetylase inhibitor panobinostat (LBH589) is mediated by direct tumor cytotoxicity and increased tumor immunogenicity. Melanoma Res 2013.
4. Kirkwood J.M., Tarhini A.A., Panelli M.C., Moschos S.J., Zarour H.M., Butterfield L.H., et al. Next generation of immunotherapy for melanoma. J Clin Oncol 2008, 26:3445-3455.
5. Marks P., Rifkind R.A., Richon V.M., Breslow R., Miller T., Kelly W.K. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer 2001, 1:194-202.
6. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002, 1:287-299.
7. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat Rev Cancer 2006, 6:38-51.
8. Piekarz R., Bates S. A review of depsipeptide and other histone deacetylase inhibitors in clinical trials. Curr Pharm Des 2004, 10:2289-2298.
9. Saito A., Yamashita T., Mariko Y., Nosaka Y., Tsuchiya K., Ando T., et al. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci USA 1999, 96:4592-4597.
10. Wang X.F., Qian D.Z., Ren M., Kato Y., Wei Y., Zhang L., et al. Epigenetic modulation of retinoic acid receptor beta2 by the histone deacetylase inhibitor MS-275 in human renal cell carcinoma. Clin Cancer Res 2005, 11:3535-3542.
11. Kato Y., Yoshimura K., Shin T., Verheul H., Hammers H., Sanni T.B., et al. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma. Clin Cancer Res 2007, 13:4538-4546.
12. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., et al. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J Clin Oncol 2005, 23:3912-3922.
13. Kato Y., Frankenne F., Noel A., Sakai N., Nagashima Y., Koshika S., et al. High production of SPARC/osteonectin/BM-40 in mouse metastatic B16 melanoma cell lines. Pathol Oncol Res 2000, 6:24-26.
14. Shibuya H., Kato Y., Saito M., Isobe T., Tsuboi R., Koga M., et al. Induction of apoptosis and/or necrosis following exposure to antitumour agents in a melanoma cell line, probably through modulation of Bcl-2 family proteins. Melanoma Res 2003, 13:457-464.
15. Welsch L., Welsch T., Dovzhanskiy D.I., Felix K., Giese N.A., Krysko D.V., et al. Impact of the histone deacetylase inhibitor 4-phenylbutyrate on the clearance of apoptotic pancreatic carcinoma cells by human macrophages. Int J Oncol 2012, 40:427-435.
16. + immunoregulatory T cells is antigen nonspecific. J Immunol 2000, 164:183-190.
17. Tao R., de Zoeten E.F., Ozkaynak E., Chen C., Wang L., Porrett P.M., et al. Deacetylase inhibition promotes the generation and function of regulatory T cells. Nat Med 2007, 13:1299-1307.
18. Gunturu K.S., Meehan K.R., Mackenzie T.A., Crocenzi T.S., McDermott D., Usherwood E.J., et al. Cytokine working group study of lymphodepleting chemotherapy, interleukin-2, and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma: clinical outcomes and peripheral-blood cell recovery. J Clin Oncol 2010, 28:1196-1202.
19. Malek T.R., Bayer A.L. Tolerance, not immunity, crucially depends on IL-2. Nat Rev Immunol 2004, 4:665-674.
20. Kato Y., Salumbides B.C., Wang X.F., Qian D.Z., Williams S., Wei Y., et al. Antitumor effect of the histone deacetylase inhibitor LAQ824 in combination with 13-cis-retinoic acid in human malignant melanoma. Mol Cancer Ther 2007, 6:70-81.
21. Hino R., Kabashima K., Kato Y., Yagi H., Nakamura M., Honjo T., et al. Tumor cell expression of programmed cell death-1 ligand 1 is a prognostic factor for malignant melanoma. Cancer 2010, 116:1757-1766.
22. Kato Y., Ozawa S., Tsukuda M., Kubota E., Miyazaki K., St-Pierre Y., et al. Acidic extracellular pH increases calcium influx-triggered phospholipase D activity along with acidic sphingomyelinase activation to induce matrix metalloproteinase-9 expression in mouse metastatic melanoma. FEBS J 2007, 274:3171-3183.
23. + memory T cells. Nature 2006, 441:890-893.
24. Moldenhauer L.M., Diener K.R., Thring D.M., Brown M.P., Hayball J.D., Robertson S.A. Cross-presentation of male seminal fluid antigens elicits T cell activation to initiate the female immune response to pregnancy. J Immunol 2009, 182:8080-8093.
25. Shoo B.A., Kashani-Sabet M. Melanoma arising in African-, Asian-, Latino- and native-American populations. Semin Cutan Med Surg 2009, 28:96-102.
26. Ishida T., Ishii T., Inagaki A., Yano H., Komatsu H., Iida S., et al. Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006, 66:5716-5722.
27. Curiel T.J., Coukos G., Zou L., Alvarez X., Cheng P., Mottram P., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004, 10:942-949.